Patent US6522324B1 successfully refreshed from Google Patents.
Patent US6066160A successfully refreshed from Google Patents.
US5266594A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
Assignee: United States Department of Health and Human Services
•
Filing: 1992-05-12
•
Granted: 1993-11-30
•
Expires: 2012-05-12
Abstract
Abstract Inhibitors of nitric acid synthase can be used to prevent neurotoxicity mediated through glutamate receptors. Nitric oxide synthase inhibitors can be used therapeutically in the treatment of vascular stroke and neurodegenerative disorders such as Alzheimer's disease and Huntington's disease.
Inventors
- 👤 Valina L. Dawson
- 👤 Ted M. Dawson
- 👤 Edythe D. London
- 👤 David S. Bredt
- 👤 Solomon H. Snyder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:22
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
35 words
A method of preventing or treating a disease condition caused by glutamate neurotoxicity in a mammal comprising: administering to a mammal in need thereof a therapeutically effective amount of an inhibitor of nitric oxide synthase.
Claim 2
Independent Claim
35 words
A method of preventing or treating a disease condition caused by glutamate neurotoxicity in a mammal comprising: administering to a mammal in need thereof a therapeutically effective amount of an inhibitor of nitric oxide synthase.
Claim 3
Dependent Claim
15 words
The method of claim 1 wherein said inhibitor is administered intravenously, intraperitoneally, intramuscularly or orally.
Claim 4
Dependent Claim
10 words
The method of claim 2 wherein said inhibitor is nitroarginine.
Claim 5
Dependent Claim
10 words
The method of claim 1 wherein said inhibitor is nitroarginine.
Claim 6
Dependent Claim
12 words
The method of claim 1 wherein said inhibitor is a nitroarginine analog.
Claim 7
Dependent Claim
11 words
The method of claim 1 wherein said disease is vascular stroke.
Claim 8
Dependent Claim
12 words
The method of claim 1 wherein said disease is a neurodegenerative disease.
Claim 9
Independent Claim
29 words
A method of preventing or treating vascular stroke in a human patient comprising: administering to a human patient a therapeutically effective amount of an inhibitor of nitric oxide synthase.
Claim 10
Independent Claim
29 words
A method of preventing or treating vascular stroke in a human patient comprising: administering to a human patient a therapeutically effective amount of an inhibitor of nitric oxide synthase.
Claim 11
Dependent Claim
15 words
The method of claim 8 wherein said inhibitor is administered intravenously, intraperitoneally, intramuscularly or orally.
Claim 12
Dependent Claim
10 words
The method of claim 9 wherein said inhibitor is nitroarginine.
Claim 13
Dependent Claim
10 words
The method of claim 8 wherein said inhibitor is nitroarginine.
Claim 14
Dependent Claim
12 words
The method of claim 8 wherein said inhibitor is a nitroarginine analog.
Claim 15
Independent Claim
25 words
A method of treating a neurodegenerative disease in a human patient comprising: administering to a human patient a therapeutically effective amount of an NOS inhibitor.
Claim 16
Independent Claim
25 words
A method of treating a neurodegenerative disease in a human patient comprising: administering to a human patient a therapeutically effective amount of an NOS inhibitor.
Claim 17
Dependent Claim
15 words
The method of claim 13 wherein said inhibitor is administered intravenously, intraperitoneally, intramuscularly or orally.
Claim 18
Dependent Claim
10 words
The method of claim 14 wherein said inhibitor is nitroarginine.
Claim 19
Dependent Claim
10 words
The method of claim 13 wherein said inhibitor is nitroarginine.
Claim 20
Dependent Claim
12 words
The method of claim 13 wherein said inhibitor is a nitroarginine analog.
Claim 21
Dependent Claim
17 words
The method of claim 13 wherein the neurodegenerative disease is Huntington's disease, Alzheimer's disease or Parkinson's disease.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-11-29 | 1997-05-31 | 1997-11-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-11-29 | 2001-05-31 | 2001-11-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-11-29 | 2005-05-31 | 2005-11-30 | $7700.00 | Window Closed / Lapsed |